[A retrospective pharmacovigilance analysis: could decreased reporting of suspected adverse reactions generate future safety concerns?].

Background: The collection and management of spontaneous reports of suspected adverse drug reactions represents a passive pharmacovigilance method for post-marketing drug safety surveillance, as it is a practical and rapid way to detect a potential warning sign. We performed an in-depth retrospective analysis of suspected adverse reaction reports in the National Pharmacovigilance Network (RNF) for the first eight months of 2019 (pre-pandemic period), 2020 (global pandemic covid-19 onset), 2021 (first post-pandemic period due to vaccine phase).

Methods: The reports of suspected adverse drug reactions were extrapolated from the National Network of Pharmacovigilance.